# Active Biotech > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/activebiotech). ## Overview Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company is headquartered in Lund, Sweden, and is listed on NASDAQ Stockholm. Active Biotech's core projects include tasquinimod for hematological malignancies, laquinimod for inflammatory eye disorders, and naptumomab for solid tumors. Their strategy involves advancing these projects to clinical proof-of-concept and securing partnerships for further development and commercialization. ## Products & services • Tasquinimod for hematological malignancies • Laquinimod for inflammatory eye disorders • Naptumomab for solid tumors • Clinical development and research services • Partnership collaborations for drug development - **Oncology Treatments** (50%) — Includes tasquinimod and naptumomab for cancer treatment - **Immunology Treatments** (30%) — Includes laquinimod for inflammatory eye disorders - **Research and Development Services** (20%) — Clinical development and research services for drug development - Tasquinimod for hematological malignancies - Laquinimod for inflammatory eye disorders - Naptumomab for solid tumors - Clinical development and research services - Partnership collaborations for drug development ## Customers Active Biotech primarily serves pharmaceutical companies and research institutions seeking innovative treatments for cancer and inflammatory diseases. Their customers are typically partners who collaborate on clinical trials and commercialization efforts. The company targets organizations looking for novel immunomodulatory therapies with high unmet medical needs. Active Biotech's partnerships are crucial for advancing their drug candidates through clinical phases and into the market. - **Pharmaceutical Companies** (primary) — Collaborate on drug development and commercialization - **Research Institutions** (secondary) — Engage in clinical trials and research collaborations - **Biotechnology Partners** (emerging) — Partner for clinical development and market entry - Pharmaceutical companies seeking innovative cancer treatments - Research institutions focused on immunology and oncology - Organizations interested in clinical trial collaborations - Partners for commercialization of drug candidates ## Geography Active Biotech is based in Lund, Sweden, and operates primarily in Europe and the United States. The company conducts clinical trials across these regions, leveraging collaborations with academic institutions and research partners. Their geographic presence is strategic for accessing key markets and research expertise. The company's partnerships with European and US institutions are vital for advancing their clinical programs and achieving regulatory approvals. - Headquartered in Lund, Sweden - Clinical trials conducted in Europe and the US - Collaborations with European academic institutions - Strategic presence in key markets for oncology and immunology ## Strategy Active Biotech's strategic priorities include advancing their clinical pipeline, securing partnerships for drug development, and achieving regulatory milestones. The company focuses on developing tasquinimod, laquinimod, and naptumomab to clinical proof-of-concept stages. Establishing collaborations with pharmaceutical companies and research institutions is crucial for commercialization. Active Biotech aims to expand their market presence by targeting high unmet medical needs in oncology and immunology. - **Advance Clinical Pipeline** (medium-term) — To reach proof-of-concept and attract partnerships - **Establish Partnerships** (short-term) — For development and commercialization support - **Regulatory Approvals** (long-term) — To enable market entry and commercialization - Advance clinical pipeline to proof-of-concept stages - Secure partnerships for drug development and commercialization - Focus on high unmet medical needs in oncology and immunology - Achieve regulatory milestones for market entry ## Risks Active Biotech faces significant risks related to pharmaceutical development, including clinical trial outcomes, regulatory approvals, and commercialization challenges. The company's financial stability depends on securing partnerships and funding for ongoing projects. Industry-specific risks include competition from other biotech firms and technological advancements. Additionally, macroeconomic uncertainties and geopolitical factors may impact financial markets and investment availability. - **Clinical Trial Outcomes** [critical] — Uncertain results can delay or halt development - **Partnership Dependence** [high] — Essential for funding and commercialization - **Regulatory Approvals** [high] — Necessary for market entry - **Competition** [medium] — Other firms may develop superior treatments - Clinical trial outcomes and regulatory approval risks - Dependence on partnerships for financial stability - Competition from other biotech firms - Macroeconomic and geopolitical uncertainties ## Accounting Active Biotech's financial reporting is influenced by the timing of clinical trial expenses and partnership revenues. The company follows IAS 34 for interim reporting, which affects how development costs are capitalized or expensed. Revenue recognition is contingent on partnership agreements and milestone achievements. The company's financial statements may also be impacted by fluctuations in research and development costs, which can vary significantly between quarters. - **Revenue Recognition** — Significant for financial results - **Clinical Trial Expenses** — High variability in costs - Timing of clinical trial expenses affects financial reporting - Revenue recognition depends on partnership agreements - IAS 34 influences interim financial reporting - Quarterly fluctuations in R&D costs impact financial statements --- *Last updated: 2026-08-11T04:04:50.690480+00:00*